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Abstract
In developed societies, the post-menopausal period covers approximately one third of a woman’s life. The deficit of oestrogens observed
during the post-menopausal period significantly affects the course of many metabolic processes, causing a number of diseases and in
consequence diminishing quality of life. Among others, bones belong to oestrogen-dependent tissues. The deficit of the protective influ-
ence of oestrogens compromises the dynamic balance of the bone transformation process towards resorption, thus reducing bone mass
and quality, while increasing the risk of low-energy fractures. In recent years, differing views on the application of oestrogen/gestagen
therapy have reached the level of controversy. The results of numerous clinical studies are far from  unequivocal, with the whole subject
one of heated debate. It has been confirmed that hormonal therapy prevents bone quality deterioration, while opening a protective
umbrella around the bone, reducing the risk of osteoporotic fractures. A rational approach to weighing possible advantages against possi-
ble risks and a thorough evaluation of a patient’s health condition allows for optimal therapy selection.
(Pol J Endocrinol 2011; 62 (1): 61–64)
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Streszczenie
W społeczeństwach rozwiniętych na okres po menopauzie przypada 1/3 długości życia kobiety. Występujący w tym czasie deficyt estro-
genów istotnie wpływa na przebieg wielu procesów metabolicznych przyczyniając się do rozwoju chorób, a w konsekwencji pogorszenia
jakości życia. Do tkanek estrogenozależnych należą między innymi kości. Brak ochronnego wpływu estrogenów prowadzi do przesunię-
cia dynamicznej równowagi przemian kostnych w kierunku resorpcji, przez co zmniejszeniu ulega masa kostna, pogorsza się jej jakość
i zwiększa ryzyko niskoenergetycznych złamań. W ostatnich latach poglądy na temat stosowania estrogenowo-gestagennej terapii hor-
monalnej stały się bardzo kontrowersyjne. Wyniki licznych badań klinicznych nie są jednoznaczne, a argumenty zarówno za, jak i prze-
ciw często podyktowane emocjami. Potwierdzono, że terapia hormonalna zapobiega pogarszaniu jakości kości oraz wpływa ochronnie na
kość zmniejszając ryzyko złamań osteoporotycznych. Racjonalna analiza korzyści w stosunku do ryzyka oraz wnikliwa ocena stanu
zdrowia pacjentek umożliwia optymalny wybór terapii. Indywidualizacja w doborze leków zmniejszających ryzyko złamań pozwala na
skorzystanie z dostępnych dobrodziejstw terapii hormonalnej z równoczesnym zachowaniem jej bezpieczeństwa.
(Endokrynol Pol 2011; 62 (1): 61–64)
Słowa kluczowe: osteoporoza, terapia hormonalna, korzyści, zagrożenia
Introduction
Climacterium is the time period between the end of the
reproductive period and the onset of ageing. Meno-
pause, when women cease to menstruate, is, in gener-
al, observed around the age of 50 (in Poland, 51.2) [1].
Afterwards, certain changes occur in a woman’s body
associated with the extinction of ovarian functions,
which terminates the secretion of sex hormones. In con-
sequence, the concentration of oestrogens falls very
quickly, especially of 17 beta estradiol and estriol. The
main oestrogen is oestrone, which is further produced
by means of the presence of aromatase enzyme in adi-
pose tissue. Hormonal changes are at the base of many
adverse symptoms, such as vasomotor symptoms (hot
flushes and sudden facial flashes), arterial blood pres-
sure variations, depression and insomnia. Metabolic
changes concern, among others, the metabolism of car-
bohydrates and lipids. Hyperinsulinism is more often
observed with abnormal glucose tolerance, revealed in
the mechanism of insulin resistance. Lipid disorders
consist of an increased cholesterol level, especially its
LDL fraction, increased synthesis of lipoprotein frac-
tion (Lp-a) and triglycerides with a parallel reduction
of HDL fraction, A1 apolipoprotein and the synthesis
of LDL receptors. Skin and mucosa quality deteriora-
tion is observed (vaginal atrophy) along with a clear
libido drop. Bone metabolism becomes disturbed, some-
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thing manifested by an increased pool of cell lines,
which mature towards osteoclasts, with a parallel in-
crease in their activity. These processes, when juxta-
posed with reduced intensity of maturation and sur-
vival of osteoblasts, shift the metabolic balance towards
increased bone resorption. These changes in bone me-
tabolism rate, with a consequent loss of bone mass (re-
duced bone mineral density) and its compromised qual-
ity, often lead to the development of osteoporosis.
The number of women of peri- and post-menopausal
age exceeds 700 million in the world. The continuous
growth of ageing, observed in developed societies, and
the greater mortality of men, unequivocally demon-
strate that the health problems of women will only grow,
with all their economic and social consequences. In
Poland, there are approximately 6 million women of
post-menopausal age, most of whom are professional-
ly active. It should be noted that, taking into account
the average lifespan of women, the post-menopausal
period occupies one third of their life.
The delay of ageing and lifespan extension have for
many years been  the subject of intensive research.
Hormonal replacement (HR) for women who have ex-
perienced the menopause seemed for a long time to be
something of a panacea for all the ailments characteris-
tic of that period of life, with the initial results of HR
very promising. After HR administration, menopausal
symptoms regressed, the comfort of life improved and
clinical observations were very optimistic.  The delayed
(by one decade) occurrence of ischaemic heart disease
and hypertension in women as against men was ex-
plained by the effects of the hormonal environment.
Knowledge of the protective effects of oestrogens on
circulation, observed during the reproductive period,
raised hopes for a similar effect of hormonal replace-
ment after menopause. The protective effects of oestro-
gens were observed on vascular walls, endothelial func-
tions, lipid profile, the metabolism of carbohydrates, and
on the system of blood clotting and fibrinolysis. Follow-
ing the theories as to the role of oestrogens in metabo-
lism control, it was expected that HR administration
could stimulate the synthesis of diastolic factors in the
vascular wall (an increased release of NO and prosta-
cyclin), suppression of hyperplasia of the smooth mus-
cular coat in coronary arteries and calcium channel
blocking. In many studies of that time, the favourable
effects of HR were observed, regarding diseases of the
cardiovascular system, including prevention of athero-
sclerosis and vasospasms, reduction of free radicals, in-
hibition of inflammatory processes, RR normalisation and
the effectiveness of primary atherosclerosis prophylac-
tics after the administration of oestrogens alone [2–4].
It was only the HERS (Heart and Estrogen/proges-
tin Replacement Study), of 2,763 women at various ages
after the menopause, which provided data on HR-as-
sociated risks. It should be emphasised that the group
of examined women was fairly differentiated, includ-
ing overweight women and those with benign breast
changes in their history, and some participants were
active smokers. Women as much as ten years after the
menopause were also included. The HERS  demonstrat-
ed an increased risk of HR-related thromboembolic com-
plications. According to the obtained results, this risk is
higher during the first year of hormonal replacement
therapy (HRT), when higher oestrogen doses and com-
bined oestrogen/gestagen therapy are applied.
Those observations triggered a certain amount of
caution and HRT-related threats were more frequently
identified. HR-related fears increased much more after
the publication of the results of the Women’s Health
Initiative Study (WHI), where the oestrogen/gestagen
arm had to be terminated before the scheduled end of
the study because of an increased incidence of cardio-
logical episodes. Additional arguments against HR have
emerged from the studies, in which an increased risk of
carcinoma of the breast, ovaries or gall bladder was ob-
served in women on chronic (> 5 years) oestrogen-ge-
stagen replacement therapy. Data from the years 2002–
–2008 demonstrated increased risks among HR-using
women for the following diseases and in the following
order: ischaemic heart disease, thromboembolic disease,
Alzheimer’s disease and cerebral strokes. Subsequent
studies into HR’s effects on diseases of the cardiovas-
cular system (WAVE, CARS, PHASE, ERA, ESPRIT) have
not confirmed the positive results of earlier observations.
The results of the above-mentioned analyses did, in
fact, strongly question the usefulness and sense of HRT
at all. Taking into consideration all the obtained data,
subsequent teams of experts withdrew their recommen-
dations for the use of HRT, and the FDA has added
oestrogens to its list of carcinogens. Only the recom-
mendation to administer HR to alleviate early meno-
pausal symptoms was maintained, albeit with the ca-
veats that the therapy duration should be “the short-
est” and the hormonal doses “the smallest” possible [5].
However, new doubts have appeared. HERS did
demonstrate an increased incidence of coronary epi-
sodes during the first year of HR therapy, but that re-
sult could have also been associated with the character-
istic features of the studied group. Hormonal therapy
was administered in women with earlier diagnosed is-
chaemic heart disease (HR as a secondary prophylactic
attempt), with inflammations of deep veins in their his-
tory and, in general, very late (as much as 10 years) af-
ter menopause.
On the other hand, it has been proven that HR, as
a primary therapy, especially when subcutaneously ad-
ministered, exerts a positive effect and does not increase
63
Endokrynologia Polska/Polish Journal of Endocrinology 2011; 62 (1)
PR
A
C
E 
PO
G
LĄ
D
O
W
E
the risk of ischaemic heart disease. An important point
in the discussion on HR values was when the chief re-
searcher of the WHI published the meaningful title:
“NIH and WHI time for a mea culpa….”, indicating that
the results of the study should be approached with cau-
tion, as their earlier interpretation seemed too simpli-
fied. Certain objections may be raised to the selection
of patients in the study group, such as large age differ-
ences, but also to the time of HR introduction, the oestro-
gen doses, higher than those recommended today, and
to the combined use of the medroxyprogesterone de-
rivative which is at present contraindicated [6, 7].
Among 26,000 examined women, in whom an in-
creased risk of myocardial infarction was diagnosed,
neither was any necessity for cardiological intervention
demonstrated (aortic-coronary bridging, coronary an-
gioplasty) nor an increased death threat. Nevertheless,
the WHI study was completed in time (still before the
scheduled deadline). Simultaneously, regarding the
continued and finished study, no increased incidence
of either myocardial infarction or breast cancer was
found in the group of women treated with oestrogens
alone (patients after hysterectomy).
A review of the studies into an increased risk of ce-
rebral stroke in women on HRT indicates that the ef-
fect is not observed in women < 60 [8]. In turn, another
study, the report from which has recently been pub-
lished, has demonstrated that women using an oral HRT
gained an advantage in terms of reduced total risk of
colon carcinoma [9].
The use of hormonal therapy (HR) raises many emo-
tions. The arguments of both proponents and oppo-
nents often lack substance, being dictated mainly by
those emotions. The negative effects of HR can be as-
cribed to several factors. The doses of oestrogen used
in the past were high, the added gestagens were de-
rived from the medroxyprogesterone group, the time
point of therapy onset was too distant from menopause,
and the participating patients had many other condi-
tions which should have excluded them from therapy,
e.g. a positive history of thrombotic phlebitis or breast
pathology.
A rational consideration of all the pros and cons and
an individual approach to each patient allows for an
optimal selection of therapy, providing the available
advantages of HR with simultaneous safety in its appli-
cation. New perspectives are opening for studies in the
field of basic sciences. Already, molecular analysis al-
lows the identification of the women likely to obtain
more advantages from HR and, conversely, those put
at higher risk by its use [10].
Building on actual knowledge, the greatest thera-
peutic benefits may be observed in those women in
whom hormonal therapy is initiated early in the peri-
menopausal period, taking into account the higher sen-
sitivity of oestrogen receptors. That period coincides
with the time when early menopausal symptoms oc-
cur. The favourable effect on the lipid profile prevails
in that time over the increased thromboembolic risk. In
younger age groups (50–59 years), hormonal therapy
decreases the risk of ischaemic heart disease and reduces
general mortality. In systemic hormonal therapy, pre-
scribed in patients after hysterectomy, it is recommend-
ed to use only 17b-estradiol-containing  preparations.
In women with a preserved uterus, the addition of
a well-selected progestagen, derived from the nortest-
osterone group, is advised.
An oestrogen/progestagen low-dose therapy is rec-
ommended, while oestrogen therapy alone should be
administered to women after hysterectomy.
At present, the primary indications for the introduc-
tion of hormonal therapy include the need for life quali-
ty improvement after menopause. Hormonal therapy is
recommended in cases of moderate and enhanced early
menopausal symptoms and related sleep disorders. Hor-
monal therapy is not recommended in women aged over
65. Nonetheless, hormonal therapy, even if introduced
at a later stage, exerts anti-fracture effects [11].
The conclusions, based on an evaluation of 30 meta-
analyses, involving 26,708 women in total, and the data
collected from 19 randomised studies between 1996 and
2008 involving 16,000 women, may confirm such a strat-
egy of management. HR reduces mortality in the group
of younger women (< 60) and provides positive effects,
not only in terms of lifespan but also quality of life at
particular age levels. [12–16].
Absolute contraindications for the use of oestrogen/
/gestagen therapy include breast cancer and endome-
trial cancer, hepatic insufficiency and active throm-
boembolic disease. Relative contraindications include
endometrial and breast cancer in family history, unex-
plained bleeding episodes from the genital tract and
thromboembolic episodes in history.
The most serious adverse effects of hormonal thera-
py include the increased risk of thromboembolic com-
plications. This risk is lowered with transcutaneous ad-
ministration and low-dose therapy. It should also be
remembered that thromboembolic complications are
not only associated with HR but are also observed in
oral contraception and with the use of drugs from the
specific oestrogen receptor modulators (SERM). Both
the hormonal therapy and SERM agents improve bone
mass volume and decrease the risk of low-energy frac-
tures in the course of perimenopausal osteoporosis [17].
Oestrogen deficit increases bone metabolism and
leads to an increased number of osteoclasts and greater
bone mass loss. Oestrogens inhibit the process of bone
resorption, thus counteracting its loss. The mechanism
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of oestrogen activity consists in suppression of the par-
ticular stages of osteoclastogenesis (recruitment, differ-
entiation, fusion and activation). Oestrogens decrease
also the production of proresorption cytokines. They
shift the metabolic balance between bone synthesis and
resorption in the anabolic direction, affecting the apop-
tosis of osteoclasts and, in mature osteoblasts, they in-
hibit the production of lisosomal enzymes. The protec-
tive effect on bone is also mediated by OPG, through
an oestrogen-induced increased expression of the gene
for osteoprotegerin.
Bone protection against osteoporotic fractures re-
duces the risk of physical disability and premature
death, thus it has a positive impact both in the medical
and the economic sense. Among women on HR thera-
py, cost savings have been observed regarding sick-
leave periods at work, treatment, rehabilitation and care
of others [18].
Notwithstanding all these facts, hormonal therapy
is not the therapy of choice in the management of post-
menopausal osteoporosis. It mainly results from the avail-
ability of other groups of medications with anti-fracture
efficacy and a good safety profile. However, a new dis-
cussion should, at least, be initiated as to whether, in the
light of new data, the earlier accepted approach to oestro-
gen therapy should be re-evaluated. Perhaps posing the
question as to which women will achieve real benefit
from HR would be more appropriate and rational than
asking why we do not propose the therapy.
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